Published in Exp Biol Med (Maywood) on January 01, 2002
TRP-ML1 functions as a lysosomal NAADP-sensitive Ca2+ release channel in coronary arterial myocytes. J Cell Mol Med (2008) 1.28
Calcium signaling in airway smooth muscle. Proc Am Thorac Soc (2008) 1.10
TPC2 proteins mediate nicotinic acid adenine dinucleotide phosphate (NAADP)- and agonist-evoked contractions of smooth muscle. J Biol Chem (2010) 1.10
ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo. Am J Physiol Renal Physiol (2008) 0.93
Nicotinic acid adenine dinucleotide phosphate (NAADP) activates global and heterogeneous local Ca2+ signals from NAADP- and ryanodine receptor-gated Ca2+ stores in pulmonary arterial myocytes. J Biol Chem (2013) 0.86
Cyclic ADP-Ribose and NAADP in Vascular Regulation and Diseases. Messenger (Los Angel) (2013) 0.78
Resveratrol, a red wine constituent, blocks the antimitogenic effects of estradiol on human female coronary artery smooth muscle cells. J Clin Endocrinol Metab (2010) 0.77
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
IgA nephropathy. N Engl J Med (2002) 5.85
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Three-dimensional, single-molecule fluorescence imaging beyond the diffraction limit by using a double-helix point spread function. Proc Natl Acad Sci U S A (2009) 4.29
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Super-resolution imaging in live Caulobacter crescentus cells using photoswitchable EYFP. Nat Methods (2008) 3.21
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension (2007) 2.77
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates. Kidney Int (2005) 2.25
Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension (2010) 2.17
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood (2010) 2.15
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Distinct renal injury in early atherosclerosis and renovascular disease. Circulation (2002) 2.01
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol (2003) 1.91
Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail (2008) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Neoangiogenesis and the presence of progenitor cells in the venous limb of an arteriovenous fistula in the rat. Am J Physiol Renal Physiol (2007) 1.88
Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant (2003) 1.86
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 1.82
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens (2008) 1.78
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension (2013) 1.76
Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol (2007) 1.75
The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension (2010) 1.74
Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation (2007) 1.72
Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant (2009) 1.71
Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol (2004) 1.70
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation (2007) 1.69
Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation (2004) 1.67
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail (2004) 1.66
Serum insulin-like growth factor-I and mammary tumor development in ad libitum-fed, chronic calorie-restricted, and intermittent calorie-restricted MMTV-TGF-alpha mice. Cancer Prev Res (Phila) (2009) 1.63
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol (2011) 1.59
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant (2013) 1.56
Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations. J Vasc Interv Radiol (2012) 1.54
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol (2009) 1.53
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension (2006) 1.52
Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant (2002) 1.52
The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol (2008) 1.51
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension (2007) 1.50
Participation bias in a population-based echocardiography study. Ann Epidemiol (2004) 1.48
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
Practical guidance: the use of social media in oncology practice. J Oncol Pract (2012) 1.44
Natriuretic peptides and therapeutic applications. Heart Fail Rev (2007) 1.44
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation (2003) 1.44
Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells (2012) 1.44
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol (2010) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res (2007) 1.41
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog Cardiovasc Dis (2009) 1.39
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail (2005) 1.39
Effect of proinflammatory cytokines on regulation of sarcoplasmic reticulum Ca2+ reuptake in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol (2009) 1.39
Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat (2003) 1.39
Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry (2010) 1.38
Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells (2010) 1.38
Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant (2005) 1.37
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant (2007) 1.37
Persistent kidney dysfunction in swine renal artery stenosis correlates with outer cortical microvascular remodeling. Am J Physiol Renal Physiol (2011) 1.35
Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation (2007) 1.34
Three-dimensional localization precision of the double-helix point spread function versus astigmatism and biplane. Appl Phys Lett (2010) 1.33
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) (2004) 1.31
Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol (2009) 1.31
Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol (2006) 1.31
Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract (2014) 1.30
Inflammatory and injury signals released from the post-stenotic human kidney. Eur Heart J (2012) 1.30
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J (2013) 1.30
HIV promoter integration site primarily modulates transcriptional burst size rather than frequency. PLoS Comput Biol (2010) 1.30
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation (2005) 1.28
Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant (2010) 1.28
Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol (2009) 1.27
Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation (2005) 1.27
The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol (2004) 1.27
Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab (2006) 1.27
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res (2007) 1.25
Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail (2004) 1.24
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol (2011) 1.24
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail (2011) 1.24
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol (2007) 1.23
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol (2005) 1.23